India, Feb. 18 -- Telix Pharmaceuticals Limited (TLX) has submitted a marketing authorization
application in Europe for TLX101-Px, its glioma imaging candidate. The submission covers major European markets. The company noted that submission of the U.S. New Drug Application will follow.
Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said: "We have been able to utilize aspects of our FDA package to expedite the European filing, which has been submitted in accordance with a pre-defined date agreed with the regulator, with the U.S. resubmission to follow."
Published by HT Digital Content Services with permission from RTT News....